Study of Methemoglobin as a Biomarker of Tissue Hypoxia During Acute Hemodilution in Heart Surgery Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01883713|
Recruitment Status : Completed
First Posted : June 21, 2013
Last Update Posted : April 17, 2018
Acute and chronic anemia continue to be associated with increased mortality in a number of clinical settings, including cardiac and non-cardiac surgery. However, "We have no clinical measures that let us know of impending insufficient oxygenation as anemia progresses" (R.B. Weiskopf). The current proposal is based on experimental and clinical data which suggest that plasma methemoglobin (MetHb) may be a sensitive biomarker of tissue hypoxia and "anemic stress" in surgical patients.
Hypothesis: Increased methemoglobin is a biomarker of tissue hypoxia during acute anemia.
Primary Objective: To demonstrate a direct relationship between decreased Hb and increased MetHb in patients undergoing acute hemodilution on cardiopulmonary bypass (CPB).
|Condition or disease||Intervention/treatment|
|Other Functional Disturbances Following Cardiac Surgery||Device: Brain Oximetry|
|Study Type :||Observational|
|Actual Enrollment :||68 participants|
|Official Title:||A Prospective Analysis of Methemoglobin as a Biomarker of Tissue Hypoxia During Acute Hemodilutional Anemia in Patients Undergoing Heart Surgery|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||August 2016|
|Actual Study Completion Date :||August 2016|
Heart surgery during CPB
All patients undergoing heart surgery using cardiopulmonary bypass who have a pre-operative Hb value greater than 90 g/L, no evidence of hypoxemia (SaO2 > 90%) and no history of congenital methemoglobinemia. Exclusion criteria will include severe hypoxemia, acute or chronic renal failure requiring dialysis, emergency surgery or the lack of a PA catheter. Non invasive brain oximetry will be used to assess the brain oxygen tension during surgical procedure.
Device: Brain Oximetry
Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
Other Name: Nonin equinox oximeter
- Arterial methemoglobin levels [ Time Frame: 18 months ]To determine if there is an association between increased methemoglobin and tissue hypoxia following heart surgery
- Cerebral tissue oxygen saturation [ Time Frame: 18 months ]
- Plasma erythropoietin levels [ Time Frame: 18 months ]
- Plasma nitrate/nitrite levels [ Time Frame: 18 months ]
- Plasma hepcidin levels [ Time Frame: 18 months ]Relationship between plasma hepcidin levels and hemoglobin levels
- Adverse outcomes including mortality, myocardial infarction, low output syndrome, stroke and renal dysfunction [ Time Frame: 18 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01883713
|St. Michael's Hospital|
|Toronto, Ontario, Canada, M5B 1W8|
|Principal Investigator:||Gregory Hare, MD, PhD||St. Michael's Hospital, Toronto|